Compare Quest Diagnostics Inc (DGX) vs Lennar Corporation (LEN) Price & Performance

Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.

The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.

LEN trades at $77.60, up 1.93% today, but faces a bearish technical outlook with recent earnings misses and declining profitability. Revenue fell to $34.19B in 2025 with net income margin dropping to 6.07%, while valuation ratios like P/E of 14.7 and P/B of 0.86 suggest potential undervaluation. Berkshire Hathaway's increased stake to 11.2% contrasts with analyst caution, as the stock hovers near support at $76 amid weak housing market sentiment.

The stock presents a value opportunity given low P/B and P/S ratios, but risks include persistent earnings underperformance, high mortgage rates pressuring housing demand, and allegations in a short report. Analyst consensus is mixed with a $77.38 price target, implying limited upside, while institutional buying by Berkshire signals long-term confidence amid near-term headwinds.